Project Name: Bexhill PCN: Pharmacist-Led Lipid Management Model of Care at PCN level

Project Summary:

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner. 

This will be achieved by the funding for an additional Lipid Pharmacist (Band 8c) to develop a new Lipid Optimisation service within the PCN.

Planned Milestones:

MilestoneDescription
1

Project Kick off meeting

Collection of baseline data

Confirmation of clinical and operational pathway, policy and protocol creation, 
and readiness to begin the clinical activity (CW Partner shall ensure that the 
clinical staff covered by the Novartis Financial Contribution are in place, 
trained and ready to begin clinical activity). 

2

CW Partner:

Collection & submission of 3 months: clinical activity data 

CW Partner & Novartis: 

Project Review meeting to discuss project progress.

3

CW Partner:

Collection & submission of 6 months: clinical activity data 

CW Partner & Novartis: 

Project Review meeting to discuss project progress.

4

CW Partner:

Collection & submission of 9 months: clinical activity data 

CW Partner & Novartis: 

Project Review meeting to discuss project progress.

5

CW Partner: 

Development of business case with 9 months data to continue the service offered by this project

6

CW Partner: 

Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary

Expected Benefits:

ANTICIPATED BENEFITS FOR PATIENTS

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
  • Enhanced experience around ASCVD with ongoing management of the condition.   
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, leveling health inequalities within the PCN. 

 

ANTICIPATED BENEFITS FOR THE ORGANISATION(S)

  • Increased proportion of ASCVD patients reviewed by primary care.    
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home.
  • Reduction in ASCVD referral rates to secondary care.
  • Increased proportion of patients receiving guideline-directed pharmacotherapy.
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care.    
  • Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES.

 

ANTICIPATED BENEFITS FOR NOVARTIS

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicines, where appropriate.
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities.
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation.  

Start Date & Duration: November 2024 for 15 months

FA-11294769-1